FAQ: Are CAR T-cells autologous?

Yes, CAR T-cells used in CAR T-cell therapy are typically autologous, meaning they are derived from the patient’s own immune cells. During the treatment process, T-cells are collected from the patient through leukapheresis, genetically engineered to express chimeric antigen receptors (CARs) and then infused back into the patient’s body. Using autologous CAR T-cells reduces the risk of immune rejection and ensures that the engineered cells are a perfect match for the patient’s immune system, potentially improving treatment efficacy.